BRAF 抑制剂的 Dimer 选择性和绑定合作性的机制
Joseph Clayton1,2, Aarion Romany1, Evangelia Matenoglou3
1Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD 21201, United States.
bioRxiv : the preprint server for biology
|January 3, 2024
概括
新的研究揭示了BRAFV600E抑制剂如何与致癌二元体结合. 了解这种机制,涉及alphaC螺旋和DFG动机,有助于设计更有效的癌症疗法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 异常的BRAFV600E信号驱动癌症,但目前的抑制剂面临抵抗.
- 滴度选择性RAF抑制剂提供了新的治疗潜力,但它们的结合机制仍然不清楚.
研究的目的:
- 阐明BRAFV600E二元化背后的分子机制和RAF抑制剂的选择性.
- 为了研究二分化和抑制剂结合对BRAFV600E构成的全效应.
主要方法:
- 在单体和二元BRAFV600E上进行了广泛的分子动态 (MD) 模拟.
- 模拟包括具有二元选择性 (PHI1) 和均能 (LY3009120) 抑制剂的阿波形式和复合物.
- 分析的重点是形状变化,结合和全沟通.
主要成果:
- 模化诱导alphaC螺旋向内移动,并增加DFG图案的灵活性.
- 抑制剂结合,特别是通过键与alphaC Glu501结合,稳定了二元相容构造.
- PHI1通过预先组织相邻的质子体进行二次抑制剂结合来表现出积极的合作性.
结论:
- 发现了BRAFV600E二元选择性的新机制,涉及全形状变化.
- 提出了一种基于共晶结构的经验方法来预测基于抑制剂二极体选择性.
- 对BRAF二分化,化和抑制剂合作性的详细见解为下一代RAF抑制剂的设计提供了信息.
更多相关视频
相关概念视频
Drug-Receptor Bonds
2.8K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
2.8K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Cooperative Allosteric Transitions
7.9K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
7.9K
MAPK Signaling Cascades
5.5K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.5K
Cooperative Binding of Transcription Regulators
6.4K
Transcriptional regulators bind to specific cis-regulatory sequences in the DNA to regulate gene transcription. These cis-regulatory sequences are very short, usually less than ten nucleotide pairs in length. The short length means that there is a high probability of the exact same sequence randomly occurring throughout the genome. Since regulators can also bind to groups of similar sequences, this further increases the chances of random binding. Transcriptional regulators form...
6.4K
Structure-Activity Relationships and Drug Design
726
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
726


